Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stock Report

Market Cap: US$2.8b

Protagonist Therapeutics Management

Management criteria checks 4/4

Protagonist Therapeutics' CEO is Dinesh Patel, appointed in Dec 2008, has a tenure of 15.83 years. total yearly compensation is $7.07M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth $19.81M. The average tenure of the management team and the board of directors is 3.8 years and 9.8 years respectively.

Key information

Dinesh Patel

Chief executive officer

US$7.1m

Total compensation

CEO salary percentage9.3%
CEO tenure15.8yrs
CEO ownership0.7%
Management average tenure3.8yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

CEO Compensation Analysis

How has Dinesh Patel's remuneration changed compared to Protagonist Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Sep 30 2019n/an/a

-US$74m

Jun 30 2019n/an/a

-US$66m

Mar 31 2019n/an/a

-US$45m

Dec 31 2018US$4mUS$520k

-US$39m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$24m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$790kUS$475k

-US$37m

Compensation vs Market: Dinesh's total compensation ($USD7.07M) is about average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Dinesh's compensation has been consistent with company performance over the past year.


CEO

Dinesh Patel (67 yo)

15.8yrs

Tenure

US$7,067,572

Compensation

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...


Leadership Team

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President15.8yrsUS$7.07m0.71%
$ 19.8m
Asif Ali
Executive VP & Chief Financial Officer2.5yrsUS$1.40m0%
$ 0
Suneel Gupta
Chief Development Officer5.8yrsUS$2.22m0.25%
$ 7.0m
Mark Smythe
Founder & VP Technology3.8yrsno datano data
Mohammad Masjedizadeh
Executive VP & Chief Technical Officer3.8yrsno datano data
Matthew Gosling
Executive VP & General Counsel4.1yrsno datano data
Carena Spivey
Head of HR & Senior VP of Human Resources3.8yrsno datano data
Ashok Bhandari
Executive VP & Chief Drug Discovery and Preclinical Development Officer3.8yrsno datano data
Carter King
Executive Vice President of Business Development3.5yrsno datano data
Abha Bommireddi
Executive Vice President of Portfolio & Program Management3.8yrsno datano data
Arturo Molina
Chief Medical Officer1.9yrsno data0.0069%
$ 192.6k
Samuel Saks
Clinical Development Advisor3.8yrsno datano data

3.8yrs

Average Tenure

60yo

Average Age

Experienced Management: PTGX's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President15.8yrsUS$7.07m0.71%
$ 19.8m
Harlan Weisman
Clinical Advisor9.8yrsno datano data
Lewis Williams
Independent Director7.3yrsUS$351.52k0%
$ 0
Chaitan Khosla
Chairman of Scientific Advisory Board9.8yrsUS$188.07kno data
Harold Selick
Independent Chairman15.7yrsUS$395.27k0.048%
$ 1.3m
William Waddill
Independent Director8.3yrsUS$364.02k0.020%
$ 567.1k
Charles Craik
Scientific Advisorno datano datano data
Mark Gallop
Scientific Advisorno datano datano data
Wayne Lencer
Clinical Advisorno datano datano data
Aida Habtezion
Clinical Advisorno datano datano data
Ellen Scherl
Clinical Advisorno datano datano data
Bryan Giraudo
Independent Director6.4yrsUS$356.52k0.031%
$ 850.7k

9.8yrs

Average Tenure

67yo

Average Age

Experienced Board: PTGX's board of directors are considered experienced (9.8 years average tenure).